Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immix Biopharma, Inc. - Common Stock (NQ: IMMX )

1.860 +0.110 (+6.29%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immix Biopharma, Inc. - Common Stock

< Previous 1 2 3 Next >
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma on Track to Dose NXC-201 Patients in United States
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words 
From Immix Biopharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering
Via Investor Brand Network
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Proposed Public Offering of Common Stock
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of care 
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
Virtual Event to be held on November 29, 2023 at 4:15 p.m. ET 
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Inc. (NASDAQ: IMMX) Climbs to New 52-Week High
Via Investor Brand Network
Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
From Immix Biopharma, Inc.
Via GlobeNewswire
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
From Immix Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.